Arcellx Past Earnings Performance
Past criteria checks 0/6
Arcellx's earnings have been declining at an average annual rate of -34.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 78.8% per year.
Key information
-34.2%
Earnings growth rate
47.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 78.8% |
| Return on equity | -14.6% |
| Net Margin | -64.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 01
Arcellx: Navigating The CAR T-Cell Revolution
Jan 30Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues
Nov 18Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 10Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth
Nov 17Arcellx: The Best Is Yet To Come
Aug 23Arcellx GAAP EPS of -$0.88
Aug 15Arcellx down 9% on day lock-up period ends
Aug 03We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely
Jun 27Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy
Jun 08Revenue & Expenses BreakdownBeta
How Arcellx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 110 | -71 | 66 | 134 |
| 30 Sep 23 | 47 | -130 | 61 | 131 |
| 30 Jun 23 | 32 | -183 | 55 | 150 |
| 31 Mar 23 | 18 | -190 | 49 | 150 |
| 31 Dec 22 | 0 | -189 | 42 | 150 |
| 30 Sep 22 | 0 | -170 | 35 | 137 |
| 30 Jun 22 | 0 | -95 | 29 | 26 |
| 31 Mar 22 | 0 | -80 | 23 | 38 |
| 31 Dec 21 | 0 | -65 | 18 | 47 |
| 30 Sep 21 | 0 | -53 | 13 | 40 |
| 31 Dec 20 | 0 | -32 | 7 | 25 |
| 31 Dec 19 | 0 | -18 | 2 | 16 |
Quality Earnings: ACLX is currently unprofitable.
Growing Profit Margin: ACLX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACLX is unprofitable, and losses have increased over the past 5 years at a rate of 34.2% per year.
Accelerating Growth: Unable to compare ACLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACLX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ACLX has a negative Return on Equity (-14.56%), as it is currently unprofitable.